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Analysis of Human Protein Replacement Stable Cell Lines
Established using snoMEN-PR Vector
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Abstract
The study of the function of many human proteins is often hampered by technical limitations, such as cytotoxicity and
phenotypes that result from overexpression of the protein of interest together with the endogenous version. Here we
present the snoMEN (snoRNA Modulator of gene ExpressioN) vector technology for generating stable cell lines where
expression of the endogenous protein can be reduced and replaced by an exogenous protein, such as a fluorescent protein
(FP)-tagged version. SnoMEN are snoRNAs engineered to contain complementary sequences that can promote knock-down
of targeted RNAs. We have established and characterised two such partial protein replacement human cell lines (snoMEN-
PR). Quantitative mass spectrometry was used to analyse the specificity of knock-down and replacement at the protein level
and also showed an increased pull-down efficiency of protein complexes containing exogenous, tagged proteins in the
protein replacement cell lines, as compared with conventional co-expression strategies. The snoMEN approach facilitates
the study of mammalian proteins, particularly those that have so far been difficult to investigate by exogenous expression
and has wide applications in basic and applied gene-expression research.
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Introduction
Methods for studying protein function often make use of either
the transient or stable expression of an exogenous gene. In human
cells this usually involves co-expression of the transgene together
with the endogenous version. This often leads to overexpression,
which can be toxic, and the presence of the endogenous protein
can reduce the ability of the introduced protein to form complexes
and interactions with cellular partners. To avoid these technical
limitations we have created a vector system for the simultaneous
targeted knock-down and replacement of endogenous proteins
with exogenous tagged versions in mammalian cells. The snoMEN
vector technology is based on the human box C/D small nucleolar
RNA (snoRNA) HBII-180C, which contains an internal sequence
(M box) that can be manipulated to make it complementary to
RNA targets [1] (see Figure 1A).
SnoRNAs are an ancient class of conserved, nuclear non-coding
RNAs (ncRNA) identified as guides for site-specific, post-
transcriptional modifications in ribosomal RNA (rRNA)
[2,3,4,5]. Box C/D snoRNAs form functional complexes in vivo
with small nucleolar ribonucleoproteins (snoRNPs), such as
NOP56, NOP58, 15.5 K and the highly conserved protein
fibrillarin, which is responsible for rRNA 29-O-ribose methylation.
The snoMEN methodology for the targeted modulation of gene
expression is an antisense gene-suppression method with applica-
tions similar to siRNA and shRNA.
Major features of snoMEN technology that may differ from
other knock-down systems are that a) snoMEN target nuclear
RNAs, e.g. pre-mRNAs and non-coding RNAs, b) snoMEN
RNAs are transcribed from RNA polymerase II promoters instead
of the RNA polymerase III promoter required for shRNA
plasmids, c) multiple snoMEN RNAs can be expressed within a
single transcript under the regulation of a single promoter [1].
This allows the use of snoMEN technology for a wide variety of
gene-regulation studies, including knock-down and/or knock-in
analysis. The RNAi technologies based on siRNA, short hairpin
RNA (shRNA), long double-stranded RNA (dsRNA), and
microRNA (miRNA) function through assembly with cellular
proteins to form an RNA-induced silencing complex (RISC)
[6,7,8] and take advantage of the endogenous gene silencing
machinery. Although the detailed snoMEN knock-down mecha-
nism is still unknown, the snoMEN vector technology can also
trigger targeted RNA degradation by a sequence-specific
RNA:RNA base pairing event. SnoMEN can function in the
nucleus and target pre-mRNA sequences, including intron
sequences [1].
The upstream binding factor (UBF) and survival of motor
neurons protein (SMN) are examples of proteins where toxic
effects of overexpression have been reported. UBF belongs to the
sequence-nonspecific class of high mobility group (HMG) proteins
and functions in RNA polymerase I transcription [9,10]. UBF1
depletion using siRNA leads to inhibition of rRNA transcription
PLOS ONE | www.plosone.org 1 April 2013 | Volume 8 | Issue 4 | e62305
Figure 1. Procedure for establishment of human protein replacement stable cell line using snoMEN. (A) Structures for targeted
endogenous SMN1/UBF1 protein replacement plasmids (pGFP–SMN1snoMENv1-PR/pmCherry–UBF1snoMENv1-PR). These constructs have three
snoMEN sequences as previously described [1], except that the M box sequences are complementary to endogenous SMN1/UBF1 pre-mRNA
sequences (See Materials and Methods). (B) Procedure of stable cell line establishment. Transfected cells were selected under G418 treatment as
previously described (http://www.lamondlab.com/f7protocols.htm). Cells were cultured for at least 14 passages before analysis to confirm stable FP–
protein and snoMEN expression. (C) Images of protein replacement stable cell lines. Expression of FP proteins was confirmed by fluorescence
imaging. Bar length is 10 mm.
doi:10.1371/journal.pone.0062305.g001
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and cell growth by increasing the number of rRNA genes in an
inactive condensed state [9]. UBF1 is a key regulator of cell size
and growth, and, therefore, UBF1 overexpression causes strong
cytotoxicity [11] (see also Figure 2A). This can explain why it has
been problematic to establish a stable cell line that stably expresses
FP-tagged UBF1 protein at a reasonable level for both imaging
and large-scale biochemical experiments. The survival of motor
neurons protein (SMN) is part of a complex involved in the
biogenesis of splicing snRNPs (small nuclear ribonucleoproteins).
SMN, together with its associated protein complex, has been
widely implicated in the assembly of macromolecular complexes
essential for splicing and ribosome subunit biogenesis [12,13,14].
Previous reports show a lethal phenotype for SMN1 knock-down
by siRNA, which induced apoptosis [15]. Also, knock-out of the
SMN1 gene in mice is known to be embryonic lethal [16].
In this study, we use the snoMEN-PR vector to establish and
characterise human cell lines where expression of either the
endogenous UBF1, or SMN, proteins has been reduced and
replaced by expression of FP-tagged versions, creating two ‘human
protein replacement’ stable cell lines. Furthermore, we investigate
the potential mechanism of snoMEN action.
Figure 2. Characterisation of snoMEN protein replacement
stable cell lines. (A) Results of proliferation/cytotoxicity assay for UBF1
(left panel) and SMN1 (right panel) protein replacement stable cell lines.
Proliferation of the HeLamCherry–UBF1-PR [UBF1-PR (stable)] and U2OSGFP–
SMN1-PR [SMN-PR (stable)] cell lines were compared with their host HeLa
and U2OS cell lines, respectively. mCherry (mCherry–C1) and GFP (GFP–
C1) expression vectors were transiently transfected into HeLa cells and
U2OS cells, respectively, as negative controls. Effects of transient
transfection for mCherry–UBF1 (mChe–UBF1), endogenous UBF1
targeted snoMEN without UBF1 expression (UBF1sno), pmCher-
ryUBF1-snoMENv1-PR, non-targeted snoMEN (CM1), endogenous
SMN1 targeted snoMEN without GFP–SMN1 expression (SMN1sno) [1],
GFP–SMN1, and pGFPSMN1-snoMENv1-PR (SMN1-PR) were also mea-
sured. Note, mChe–UBF1 and SMN1sno showed cytotoxic effects when
transiently transfected into HeLa cells and U2OS cells, respectively,
however, this cytotoxicity was rescued by transfection of UBF1-PR and
SMN1-PR. (B) Localisation analysis of endogenous UBF1 (arrow) and
mCherry–UBF1 (arrow heads) protein in HeLa cells (HeLa) and
HeLamCherry–UBF1-PR cells (UBF1-PR). Images show localisation pattern
of DNA (DAPI, Blue), endogenous UBF1 (TRITC)/mCherry–UBF1 proteins
(mCherry, Red), and endogenous RPA194 protein (Green) stained as a
Fibrillar Centre (FC) marker [47]. An example of transiently transfecting
the mCherry–UBF1 expression plasmid without replacement in HeLa
cells is shown in the lower panel (mChe–UBF1). Transiently transfected
cells did not show the correct localisation pattern with endogenous
UBF1, i.e. FC and nucleoplasm but not Dense Fibrillar Components
(DFC) and Granular Components (GC). In addition, these transiently
transfected cells show a cytotoxic phenotype (see also Figure 1A). Scale
bar is 10 mm. (C) Localisation analysis of endogenous SMN1 (arrow) and
GFP–SMN1 (arrow heads) protein in U2OS cells (U2OS), U2OSGFP–SMN1-PR
stable cells (SMN1-PR), and U2OSGFP–SMN1 stable cells (GFP–SMN1).
Images show localisation pattern of DNA (DAPI, Blue), endogenous
SMN1 (FITC)/GFP–SMN1 proteins (GFP, Green), and endogenous p80
coilin protein (Red) stained as a Cajal body marker [47]. Scale bar is
10 mm. (D) Expression level of either endogenous UBF1 and mCherry–
UBF1 (upper panel), or SMN1 and GFP–SMN1 (lower panel), were
measured by western blot analysis. The graphs show average signal
intensity and standard deviation for three independent experiments
from the same stable clone selected. In the upper panel, the UBF1/
mCherry–UBF1 signal ratio was normalised to the tubulin signal. Images
on the right side show examples of western blots of UBF1 and SMN1
from established stable cell lines. Ratios were calculated by comparison
with endogenous UBF1 and SMN1 signals in control, untransfected
cells. An equivalent amount of total cell extract from HeLa cells (HeLa)
and HeLamCherry–UBF1-PR cells (UBF1-PR) was loaded for each lane and
the proteins separated by SDS PAGE, electroblotted and probed both
with a monoclonal anti-UBF1 antibody and with an anti-tubulin
antibody as a loading control. The lower panel shows the same
experiment as the upper panel, except SMN1 was detected from U2OS
cells (U2OS), U2OSGFP–SMN1-PR stable cells (SMN1-PR), and U2OSGFP–SMN1
(GFP–SMN1) stable cells. (E) Gene-expression profiles were compared
between U2OS cell and U2OSGFP–SMN1-PR cells by quantitative mass
spectrometry analysis. Comparison of expression level of mass
spectrometry detected proteins for U2OS cell and U2OSGFP–SMN1-PR
cells. Each SILAC experiment was independently repeated at least three
times. Correlation between protein ratios of SILAC experiments
visualised on a 2D logarithmic graph for all proteins, identified as
previously described [48,49]. On the x and y axis, log2 (H/L ratio)
correlates with the enrichment in U2OS cells and U2OSGFP–SMN1-PR cells
for experiment 1 and experiment 2, respectively. Graph shows a
distribution pattern of plot numbers. SILAC ratio values of labelled
proteins are listed in Table S1.
doi:10.1371/journal.pone.0062305.g002
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Materials and Methods
Cell Culture and Plasmid Construction
HeLa and U2OS cells were provided from EMBL and ATCC,
respectively. HeLa and U2OS cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS). All plasmid transfections were performed
using effectin (QIAGEN) as described by the supplier.
SnoMEN vectors were established as previously shown [1]. The
sequence spanning exon 2 to exon 3 of the C19orf48 gene was
inserted 39 of the EGFP–SMN1/mCherry–UBF1 mammalian
expression plasmid (Invitrogen), creating the snoMEN protein
replacement vector (Figure 1A). M box sequence of HBII-180C
cDNA (59-CACCCCTGAGGACACAGTGCA-39) was modified
to create complementary sequences to target genes as follows;
SMN1:59-ATTAGAACCAGAGGCTTGACG-39, 59-
GCACTGGCTGCGACCTCACCT-39 and 59-TTACAT-
TAACCTTTCAACTTT-39, UBF1:59-ACCAACGGTCTGG-
TAAAGAGT-39, 59-GGATCAGTTACCTCATTAGAA-39 and
59-CCCACCTTAACTCTCCTCCCC-39.
Microscopy and Antibodies
All cell images were recorded using the DeltaVision Spectris
fluorescence microscope (Applied Precision). Live cell images for
HeLamCherry–UBF1-PR cells U2OSGFP–SMN1-PR were prepared as
previously described (http://www.lamondlab.com/f7protocols.
htm). Cells were imaged using a 606 (NA 1.4) Plan Apochromat
objective. Twelve optical sections separated by 0.5 mm were
recorded for each field and each exposure (SoftWoRx image
processing software, Applied Precision). Primary antibodies against
UBF1 (F-9, Santa Cruz), SMN1 (BD Transduction Laboratories),
RPA194 (C-1, Santa Cruz), tubulin (DM1A, Sigma), coilin (5P10)
[17], fibrillarin (72b9) [18], Ago1 (D84G10, Cell Signaling
Technology), Ago2 (C34C6, Cell Signaling Technology), and
Upf1 (Cell Signaling Technology) were prepared for immuno-
staining and/or western blotting.
Proliferation/cytotoxicity Assay
Proliferation/cytotoxicity assay were performed using alamar-
Blue (AbD serotec) as described by the supplier. Fluorescence was
measured using an ELx800 plate reader (BioTek).
Quantification Analysis of Blotting Images
All signal intensities of blotting images were analysed by
imaging software (Image Gauge v4.21; Fujifilm) using manufac-
turer’s procedure. Briefly, the same size of pixel area was selected
and signal intensity calculated by subtraction the background
signal. Each signal was normalised with reference to standard
control signals, e.g. tubulin, and a signal/control ratio was
calculated.
SiRNA experiments. SiRNA was transfected by Lipofecta-
mine RNAiMAX (Invitrogen) according to the manufacturer’s
instructions. Scrambled siRNA, which does not have an RNA
target (Dharmacon), and either SMN1 siRNA (59-CCAAAUG-
CAAUGUGAAAUAUU-39) or UBF1 siRNA (59-AAAAGUAG-
CAUUUAAAGACUU-39) (siMAX siRNA, MWG operon) were
transfected as negative and positive controls, respectively. The
SMN1 M box siRNAs, targeted to the same intronic sequences as
used for the SMN1-PR/UBF1-PR snoMEN, were synthesised and
transfected (SMN1 Mbox siRNA-1:59-CGUCAAGCCUCUG-
GUUCUAAU-39, SMN1 Mbox siRNA-2:59-AGGUGAGGUCG-
CAGCCAGUGC-39, SMN1 Mbox siRNA-3:59-AAAGUU-
GAAAGGUUAAUGUAA-39, UBF1 Mbox siRNA-1:59-
ACUCUUUACCAGACCGUUGGU-39, UBF1 Mbox siRNA-
2:59-UUCUAAUGAGGUAACUGAUCC-39 UBF1 Mbox
siRNA-3:59-GGGGAGGAGAGUUAAGGUGGG-39) (siMAX
siRNA, MWG operon).
Fibrillarin, Upf1/Rent1, Argonaute-1 (Ago1)/EIF2C1, Argo-
naute-2 (Ago2)/EIF2C2 siRNAs (On-Targetplus SMART pool
product, Dharmacon) were also transfected into U2OSGFP–SMN1-
PR/U2OSGFP–SMN1 stable cell lines using Lipofectamine RNAi-
MAX.
ShRNA experiments. Plasmids to produce shRNAs were
constructed using pLVX-shRNA2 vector (Clontech). SMN1
shRNA (59-AGCGATGATTCTGACATTT-39)/UBF1 shRNA
(59-CGGAGAAGAAGAAGATGAA-39) and M box shRNAs
were transfected as positive and negative controls, respectively.
M box shRNA sequences are as follows; SMN1 Mbox shRNA-
1:59-GTCAAGCCTCTGGTTCTAA-39, SMN1 Mbox siRNA-
2:59-GGTGAGGTCGCAGCCAGTG-39, SMN1 Mbox siRNA-
3:59-AAGTTGAAAGGTTAATGTA-39, UBF1 Mbox siRNA-
1:59-CTCTTTACCAGACCGTTGG-39, UBF1 Mbox siRNA-
2:59-TCTAATGAGGTAACTGATC-39 UBF1 Mbox siRNA-
3:59-GGGAGGAGAGTTAAGGTGG-39.
Immunoaffinity Purification of FP–SMN1/FP–UBF1
Complexes and Stable Isotope-labelling of Cellular
Proteins
SILAC experiments were performed as previously described
[19,20,21,22,23]. Cells were grown for at least six cell divisions in
L-arginine-, L-arginine 13C6
14N4-, or L-arginine
13C6
15N4-
labelling media before analysis. Nuclei were isolated from cells
using a variation of a previously described technique (http://www.
lamondlab.com/f5nucleolarprotocol.htm). Purified nuclei were
resuspended in RIPA buffer to solubilize proteins. Lysates from
each cell line were mixed in a 1:1:1 ratio based on total protein
concentration, and FP proteins were affinity purified using anti-
GFP/anti-mCherry monoclonal antibodies (GFP–TRAP_A/
RFP–TRAP_A, Chromotek).
Isolated nuclear proteins were separated on NuPAGE 4–12%
Bis-Tris gel and the gel cut into 12 slices. Peptides resulting from
in-gel digestion were extracted from the gel pieces, desalted and
concentrated on reverse-phase C18 tips, and eluted into 96-well
plates for automated mass spectrometry analysis.
Mass Spectrometry and Data Analysis
Liquid chromatography-Tandem Mass Spectrometry was per-
formed using an Ultimate U3000 nanoflow system (Dionex Corp)
and a linear ion trap-orbitrap hybrid mass spectrometer (LTQ-
Orbitrap XL and Velos, Thermo Fisher Scientific Inc.) via a
nanoelectrospray ion source (Proxeon Biosystems) as described
previously [20]. Data were acquired using Xcalibur software, and
quantification was performed using MaxQuant [24,25] and the
Mascot search engine (Matrix Science) for peptide identification
against the International Protein Index (IPI) human protein
database. The initial mass tolerance was set to 7 p.p.m., and MS/
MS mass tolerance was 0.5. Enzyme was set to trypsin/p with up
to 3 missed cleavages. Carbamidomethylation of cysteine was
searched as a fixed modification, whereas N-acetyl-protein, and
oxidation of methionine were searched as variable modifications.
A minimum of two peptides were quantified for each protein. An
in-house developed software program was used to evaluate peptide
identifications and abundance ratios.
snoMEN:snoRNA Modulator of Gene Expression Vector
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Results
Establishment of Human Protein Replacement Stable Cell
Lines Using snoMEN-PR Vector
Two human protein replacement stable cell lines,
HeLamCherry–UBF1-PR and U2OSGFP–SMN1-PR were established
using a procedure previously described [26,27] except the plasmid
used was snoMEN-PR (Figure 1). This resulted in reduced
expression of endogenous UBF1 and SMN1 and their replacement
with mCherry–UBF1 and GFP–SMN1, respectively. Two vectors
expressing M box-modified snoRNAs targeted to endogenous
UBF1 and SMN1 pre-mRNAs were constructed, based on the
previous snoMEN design [1]. Plasmids pmCherry–UBF1sno-
MENv1-PR and pGFP–SMN1snoMENv1-PR encode mCherry–
UBF1 and GFP–SMN1 cDNA, respectively, for the knock-in of
the FP-tagged UBF1 and SMN1, and three M box-modified
snoRNAs, each targeted to different exon–intron junction
positions within endogenous UBF1 and SMN1 pre-mRNAs, for
the knock-down of expression of the endogenous gene (Figure 1A)
(see also methods, Figure 3A and B). pmCherry–UBF1sno-
MENv1-PR and pGFP–SMN1snoMENv1-PR, which also contain
the neomycin-resistance gene, were transfected into HeLa and
U2OS cells, respectively (Figure 1B). Twenty four hours after
transfection, G418 was added into the culture medium for
selection of transfected cells. After two weeks of G418 selection,
multiple positive clones were independently chosen and assigned
as passage 1 (p1) and cultured for more than 14 passages before
analysis to confirm stable expression of FP-tagged proteins
(Figure 1B). Both stable cell lines, HeLamCherry–UBF1-PR and
U2OSGFP–SMN1-PR, show expression of FP-tagged proteins at
levels sufficient for imaging by fluorescence microscopy (Figure 1C
and see also Figure S1A).
Characterisation of snoMEN-PR Stable Cell Lines
The growth rate of each stable cell line was examined by a
proliferation assay (Figure 2A). Both HeLamCherry–UBF1-PR [left
panel, UBF1-PR (stable)] and U2OSGFP–SMN1-PR [right panel,
SMN1-PR (stable)] cell lines show similar growth rates compared
with host cells, i.e. HeLa and U2OS cells, respectively. Transient
transfection of mCherry–C1, which expresses mCherry protein
alone, and pmCherry–UBF1snoMENv1-PR (UBF1-PR), did not
cause either cytotoxicity, or growth suppression. However,
transient transfection of mCherry–UBF1 expression plasmid
(mChe–UBF1) and UBF1 snoMEN expression plasmid (UBF1sno)
resulted in both cytotoxicity and growth suppression, consistent
Figure 3. SiRNA and shRNA knock-down targeted to endoge-
nous pre-mRNAs. (A) & (B) The targeted regions on the RNAs for each
of the snoMEN vectors used in this study are shown in a schematic
diagram. The same pre-mRNA sequence of UBF1 (A)/SMN1 (B) as
targeted by the snoMEN vector was targeted by siRNA oligoribonucleo-
tides and shRNA expression plasmids. (C) Western blot analysis for
siRNA experiments. Detection of endogenous UBF1 protein levels
following transfection of HeLa cells using either Scrambled siRNA
(Control: lane1), UBF1 siRNA (siUBF1: lane2), UBF M box siRNA-1 (siUM1:
lane3), UBF M box siRNA-2 (siUM2: lane4), and UBF M box siRNA-3
(siUM3: lane5). An equivalent amount of HeLa extract was loaded for
each lane and the proteins separated by SDS PAGE, electroblotted onto
membrane and probed both with a monoclonal anti-UBF1 antibody
and with an anti-tubulin antibody as a loading control. Graph shows
UBF1 signal intensity normalised to the tubulin signal measured from
three independent experiments. (D) Structure of shRNA expression
plasmids. A cDNA producing a short hairpin RNA was subcloned under
the U6 RNA polymerase III promoter. Each of the shRNA plasmids
encode ZsGreen FP–protein cDNA under CMV promoter regulation as a
transfection marker. (E) UBF1 shRNA plasmid and no-endogenous
target shRNA plasmid were transfected as a positive and negative
control, respectively. UBF1 Mbox shRNA-1 to -3 (shUM1–3) have the
same target sequence as UBF1 snoMEN from set1 to set3, respectively
(Figure 3A). Scale bar, 10 mm. Arrow: cells not showing knock-down,
Arrowhead: cells showing knock-down. (F) Western blot analysis for
shRNA experiments. Detection of endogenous UBF1 protein levels
following transfection of HeLa cells using either Scrambled shRNA
(Control: lane1), UBF1 shRNA (shUBF1: lane2), UBF M box shRNA-1
(shUM1: lane3), UBF M box shRNA-2 (shUM2: lane4), and UBF M box
shRNA-3 (shUM3: lane5). An equivalent amount of HeLa extract was
loaded for each lane and the proteins separated by SDS PAGE,
electroblotted onto membrane and probed both with a monoclonal
anti-UBF1 antibody and with an anti-tubulin antibody as a loading
control. Graph shows UBF1 signal intensity normalised to the tubulin
signal measured from three independent experiments.
doi:10.1371/journal.pone.0062305.g003
snoMEN:snoRNA Modulator of Gene Expression Vector
PLOS ONE | www.plosone.org 5 April 2013 | Volume 8 | Issue 4 | e62305
with previous studies [9,11] (Figure 2A left panel, see also
Figure 2B mChe–UBF1). These results suggested that the previous
problems of cytotoxicity/growth-suppression upon UBF1 overex-
pression/depletion were circumvented with snoMEN protein
replacement. Thus, even although the level of protein replacement
is not complete, it is sufficient to rescue cell viability. The growth
rate of the HeLamCherry–UBF1-PR stable cell line, which stably
expresses mCherry–UBF1 and constitutively knocks down endog-
enous UBF1 expression, is normal.
Transient transfection of GFP–C1 (expressing GFP protein
alone), CM1 (which expresses snoMEN with no endogenous target
[1]), GFP-SMN1, and pGFP–SMN1snoMENv1-PR (SMN1-PR)
did not cause either cytotoxicity, or growth suppression. However,
transient transfection of the SMN1 snoMEN expression plasmid
(SMN1sno) resulted in cytotoxicity, consistent with previous
studies [1,15,26] (Figure 2A right panel). These results suggested
that the cytotoxicity caused by SMN1 depletion was rescued by
snoMEN protein replacement and that the growth rate of the
U2OSGFP–SMN1-PR stable cell line, which stably expresses GFP–
SMN1 and constitutively reduces endogenous SMN1 expression,
was normal.
The localisation patterns of the tagged proteins in the
HeLamCherry–UBF1-PR and U2OSGFP–SMN1-PR stable cell lines were
examined by immunostaining. In both stable cell lines, the tagged
UBF1 and SMN1 proteins co-localise with nucleolar and Cajal
body marker proteins, i.e. RPA194 and coilin, respectively,
consistent with the localisation pattern of the endogenous proteins
(Figure 2B and C, arrowhead and arrow). In the case of mCherry–
UBF1 overexpression, the majority of the tagged protein shows no
co-localisation with RPA194 in nucleoli (Figure 2B mChe–UBF1)
and these transfected cells show a cytotoxic phenotype after 24
hours.
Western blot analysis was performed to measure the protein
replacement ratio for HeLamCherry–UBF1-PR and
U2OSGFP–SMN1-PR stable cell lines (Figure 2D). Both cell lines
show about 40% reduction of the levels of endogenous UBF1/
SMN1 proteins and 30–40% knock-in of FP-tagged proteins
(Figure 2D, graphs UBF1-PR and SMN1-PR). It was not possible
to generate a stable cell line for the overexpression of mCherry–
UBF1 that also stably expressed the FP-tagged protein, which is
consistent with the results of the proliferation assay (Figure 2A) and
also as reported in a previous study [11]. To establish protein
replacement stable cell lines, clones were selected where the FP-
tagged protein was expressed only at a level comparable to the
level of knock-down of the endogenous protein, thereby avoiding
net overexpression.
The expression profile of a wide range of genes in both
U2OSGFP–SMN1-PR and HeLamCherry–UBF1-PR stable cell lines was
compared using SILAC (Stable Isotope Labelling of Amino acids
in Cell culture) quantitative mass spectrometry (MS) analysis
[19,20,21,22,28] (Figure 2E and Figure S1B). From the approx-
imately 700 proteins detected by MS, more than 680 proteins
(97.4%) showed less than a two-fold difference in expression
between host cells and snoMEN-PR stable cells. In combination,
these results demonstrate the establishment of human protein
replacement stable cell lines, including a cell line previously not
technically possible, using the snoMEN-PR vector.
Comparison of siRNA/shRNA and snoMEN RNA
Interference
The data above show that M box-modified snoRNAs can
reduce expression of endogenous cell proteins when targeted to
sequences within introns of pre-mRNAs and intron/exon junction
sequences that are not present in the mature mRNA. We
compared this with the ability of siRNA oligoribonucleotides to
knock-down expression of both the UBF1 and SMN1 proteins
when targeted against the same intronic sequences (Figure 3 and
Figure S2). Therefore, for both UBF1 and SMN1, three siRNA
oligonucleotides per gene complementary to the same exon-
intron/intron sequences in either UBF1, or SMN1, pre-mRNAs as
targeted by the M box-modified snoRNAs in pmCherry–
UBF1snoMENv1-PR and pGFP–SMN1snoMENv1-PR, were
transfected into HeLa and U2OS cells (Figure 3A and B). All
three intron-targeted siRNAs (siUM1–3) showed little or no knock-
down of UBF1, as did a further negative control siRNA, as judged
by protein blotting (Figure 3C) and by immunofluorescence (data
not shown). As a positive control, another siRNA targeted to
UBF1 exon 3 sequence (siUBF1), resulted in ,50% knock-down.
A similar result was obtained using three siRNAs targeted to
introns 1 & 7 of SMN1 (siSM1–3), which also failed to knock-
down, as did a further negative control siRNA, while a positive
control siRNA targeted to SMN1 exon 8 reduced SMN1 levels by
,30% as judged by both immunofluorescence and protein
blotting analyses (Figure S2A and B). Furthermore, the same
series of analyses were performed using shRNA technology
(Figure 3A, B, D, E and F Figure S2C and D). Three shRNA
expression plasmids per gene, complementary to the same exon–
intron/intron sequences in either UBF1, or SMN1 pre-mRNAs, as
targeted by the M box-modified snoRNAs in pmCherry–
UBF1snoMENv1-PR and pGFP–SMN1snoMENv1-PR, were
transfected into HeLa and U2OS cells (Figure 3A, B, and D).
All three intron-targeted shRNAs (shUM1–3) showed little or no
knock-down of UBF1, compared with non-transfected cells
(Figure 3E and F). As a positive control, another shRNA plasmid
targeted to a UBF1 exon 5 & 6 sequence (shUBF1), resulted in
,30% knock-down. A similar result was obtained using three
shRNA expression plasmids targeted to the intron of SMN1,
which showed little or no knock-down of expression compared
with non-transfected cells, while a positive control shRNA plasmid
targeted to SMN1 exon 2 sequence reduced SMN1 levels by
,70% (Figure S2C and D).
We conclude that the snoRNA vectors can target RNA
sequences to reduce expression of genes, including targets that
are not amenable to knock-down by both siRNA and shRNA
mechanisms. The combined results indicate that the mechanism of
knock-down is dependent on snoRNA expression, that snoRNAs
are nuclear and that they can knock-down target intron RNA
sequences that are not present in cytoplasmic mRNA.
Little is known about the molecular mechanism of gene
regulation by snoRNAs. However, some snoRNAs have been
reported to associate with Argonaute proteins (Ago1, or Ago2),
which are involved in the main RNAi pathway [29]. Therefore,
we examined whether RNAi-mediated depletion of several
proteins, including Ago2, could affect the snoMEN machinery
(Figure 4). This result showed that the gene suppression effect of
the snoMEN against SMN was reduced in either Ago2, up-
frameshift-1 (Upf1), or fibrillarin depleted cells, compared to the
control in lane 1 (Figure 4). This implies that these proteins may be
involved, either directly or indirectly, in the mechanism of
snoMEN-mediated gene suppression. Interestingly, depletion of
Upf1, which is thought to be essential to nonsense-mediated decay
(NMD) [30,31,32], also prevented the inhibition of gene expres-
sion by snoMEN. We have previously shown that both box C and
box D motifs are required for snoMEN expression [1]. Fibrillarin
binds endogenous snoRNAs via a box C-D base paired structure,
termed the k-turn, and is necessary for snoRNA maturation and
expression. Therefore, depletion of fibrillarin might decrease
snoMEN expression levels and thereby prevent the gene
snoMEN:snoRNA Modulator of Gene Expression Vector
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suppression effect (Figure S3). Taken together, our results suggest
that snoMEN might modulate target gene expression via a
mechanism involving Ago2 and/or Upf1.
MS Pull-down Assay of FP-proteins Using snoMEN-PR
Stable Cell Lines
The establishment of snoMEN-PR stable cell lines led us to
examine how they may be used for large-scale biochemical
experiments, such as pull-down assays. Two series of quantitative,
MS-based SILAC proteomics experiments were used to char-
acterise a) changes in UBF1 complexes in either the absence, or
presence, of low concentrations of Actinomycin-D, i.e. comparing
when RNA polymerase I is either active, or inactive, respectively
(Figure 5A left panel, and see also Figure S4), b) differences in the
incorporation ratio into in vivo SMN1 complexes between over
expression (U2OSGFP–SMN1) and protein replacement stable cells
(U2OSGFP–SMN1-PR) (Figure 5A, right panel). HeLamCherry–UBF1-PR
and a triple isotope SILAC labelling scheme was employed [19].
Control HeLa/U2OS cells were cultivated in medium containing
the normal, ‘‘light’’ amino acids, while cells stably expressing
mCherry–UBF1/GFP–SMN1 were grown either with ‘‘medium’’
(no treatment/without endogenous SMN1 replacement), or with
‘‘heavy’’ (Actinomycin-D treatment/with endogenous SMN1
replacement), isotope-labelled amino acids. The conditions of
Actinomycin-D treatment were carefully titrated (Figure S4) [28].
Soluble cell extract was prepared from each of the light, medium,
and heavy cell cultures; mCherry–UBF1/GFP–SMN1 and
associated partners were affinity purified and tryptic peptides
were analysed by MS. Intensity ratios for the three isotopic forms
of each protein were determined using MaxQuant [24,25]and
analysed. Data were plotted in 2D logarithmic graphs separately
for UBF1 (Figure 5B) and SMN1 (Figure S5A).
The result of the UBF1 pull-down is shown in Figure 5B: the x
axis represents enrichment of mCherry–UBF1-associated proteins
in comparison with the control IP (medium/light ratio) and the y
axis represents enrichment of mCherry–UBF1-associated proteins
in Actinomycin-D-treated versus untreated cells (heavy/light
ratio). Contaminant proteins are clustered around the origin,
while proteins specifically co-purifying with mCherry–UBF1 in
untreated cells appear on the upper right of the graph. Proteins
whose specific co-purification with mCherry–UBF1 decreased
upon treatment with Actinomycin-D appear below the 1:1 line
(Figure 5B, dashed blue line). The UBF1 ratio is 1:1, as expected,
which means that the same amount of UBF1 protein was pulled
down in both conditions (i.e. with and without Actinomycin-D
treatment). Many of the UBF1 directly/indirectly associated
proteins that were quantified, e.g. hnRNPA1, TCOF1 (Treacle),
CK2A2 (Casein kinase II, alpha 1), POLR1A (polymerase (RNA) I
polypeptide A), and CDK2 (Cyclin dependent kinase 2)
[33,34,35,36], also showed little or no change in ratio, similar to
UBF1. However, the ratio of other proteins, especially those
associated with chromatin remodelling, e.g. SMARCA5/SNF2h
(SWI/SNF related, matrix associated, actin dependent regulator of
chromatin, subfamily a, member 5), WSTF (Williams syndrome
transcription factor) [37], was decreased by Actinomycin-D
treatment (Figure 5C).
In Figure 5D and Figure S5, displaying the data from the GFP–
SMN1 pull-down assay, the x axis represents enrichment of GFP–
SMN1-associated proteins (protein replacement cell line IP versus
the control IP: heavy/light ratio) and the y axis represents
enrichment of GFP–SMN1-associated proteins (over-expression
cell line IP versus the control IP: medium/light ratio) (Figure S5).
Contaminant proteins are clustered around the origin, while
proteins specifically co-purifying with GFP–SMN1 in over
expressed cells appear to the bottom right of the graph. Proteins
whose specific co-purification with GFP–SMN1 increased in
protein replacement, compared with over expression, appear
above the 1:1 line (Figure S5A and B, dashed red line).
Interestingly, the pull-down ratio of SMN1 in the replacement
cell line shows a more than 2-fold increase compared with the
over-expression cell line, even though GFP–SMN1 expression in
the replacement cell line is less than 40% of the endogenous
protein level (Figure 2D, Figure 5D and Figure S5B). As well as
SMN1, the majority of the previously identified nuclear SMN1
interaction partners, e.g. Gemin family proteins (Gemin2, 5, and
8), also show an increased SILAC ratio in the replacement cell line
Figure 4. Potential factors involved in snoMEN machinery. (A)
U2OSGFP–SMN1-PR and U2OSGFP–SMN1 cells were transfected with either
Scrambled siRNA, Ago1 siRNA, Ago2 siRNA, Upf1 siRNA, or fibrillarin
siRNA. An equivalent amount of each extract was loaded in each lane
and the proteins were separated by SDS PAGE, electroblotted onto
membrane and probed with anti-SMN1, anti-Ago1, anti-Ago2, anti-
Upf1, anti-fibrillarin and with anti-tubulin as a loading control. (B) The
graphs show average SMN signal intensity and standard deviation for
three independent experiments using the same procedure as in A. SMN
signal ratio was normalised to the tubulin signal.
doi:10.1371/journal.pone.0062305.g004
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compared with the overexpression cell line (Figure 5D and Figure
S5B). It is known that SMN1 forms an octamer complex both
in vivo and in vitro [38]. These results suggest that FP-tagged SMN1
protein is likely incorporated into endogenous complexes more
efficiently in the SMN1 replacement cell line, U2OSGFP–SMN1-PR,
than in a typical overexpression stable cell line, U2OSGFP–SMN1
(see also a model in Figure S5C).
Discussion
In this study we describe the establishment of human protein
replacement stable cell lines using the snoMEN vector technology
(snoMEN-PR) and analyse these snoMEN-PR stable cell lines
using fluorescence microscopy and quantitative mass spectrome-
try. The snoMEN vector was derived from a human box C/D
snoRNA (HBII-180C). We demonstrated previously that the
modified HBII-180C snoRNA backbone, i.e. snoMEN, could
modulate targeted gene expression for both cellular genes and G/
YFP-fusion proteins, using transient transfection methods [1].
Gene knock-down is mediated via a short internal snoRNA region,
termed the M box, which can be manipulated to make it
complementary to a target RNA sequence of choice. Briefly, the
major differences between snoMEN technology and other knock-
down systems are a) snoMEN target nuclear RNAs, e.g. pre-
mRNAs and non-coding RNAs, b) snoMEN RNAs are tran-
scribed from RNA polymerase II promoters instead of the RNA
polymerase III promoter required for shRNA plasmids, c) multiple
snoMEN RNAs can be incorporated within a single transcript
under the regulation of a single promoter [1] (Figure 6).
We show here for two separate proteins, i.e., UBF and SMN,
that a subset of the total pool of endogenous protein can be
knocked down and that fraction replaced by an exogenous, tagged
version of the same protein, that is expressed from the same
transcript in the same vector that is used for the knock-down. Even
although the efficiency of replacement here is partial, it is
nonetheless demonstrated to be sufficient to allow the establish-
ment of stable cell lines for proteins that are toxic when simply
overexpressed in the presence of unaltered levels of the endoge-
nous factors. This demonstrates the value of the approach, which
is further illustrated by the observation, based upon immunopre-
cipitation experiments, that there is more efficient incorporation of
the tagged, exogenous version of proteins into multiprotein
complexes in the snoMEN-PR cell lines as compared with cells
overexpressing the tagged protein in competition with the
endogenous version. It should be noted that it is always to be
expected that knock-down strategies will in practice result in
incomplete removal of the targeted protein and that only
Figure 5. Characterisation of FP–protein complexes in replace-
ment stable cell lines by Quantitative SILAC Proteomic
analysis. (A) Design of the triple-encoding SILAC pull down
experiments (see text). Comparison of mCherry–UBF1 complex, either
in the presence, or absence, of low concentration Actinomycin-D (left
panel) and comparison of GFP–SMN1 complex either with replacement
(U2OSGFP–SMN1-PR), or without replacement (U2OSGFP–SMN1) (right panel).
The SILAC experiments were independently repeated at least four
times. (B) SILAC result of mCherry–UBF1 complex pull down assay
visualised on a 2D logarithmic graph for all proteins identified. On the x
axis, log2 (M/L ratio) correlates with the enrichment in mCherry–UBF1 IP
versus control IP. On the y axis, log2 (H/L ratio) correlates with the
enrichment in mCherry–UBF1 IP with Actinomycin-D treatment versus
no-treatment IP. The bait, UBF1, is shown in red, and a blue line
separates the proteins whose interaction with UBF1 is increased (above
the line)/or decreased (below) after Actinomycin-D treatment. Known
interaction partners, which were identified and quantified, are also
highlighted. SILAC ratio values of labelled proteins are listed in Table S2.
(C) Known UBF1 interaction partners, which were identified and
quantified. Graph shows fold change of each protein ratio with
Actinomycin-D treatment (red) and without treatment (orange)
measured from five independent experiments. (D) Comparisons of
protein ratios of known interaction partners of SMN1 between over
expression stable cell line (U2OSGFP–SMN1; light green) and protein
replacement stable cell line (U2OSGFP–SMN1-PR; green) measured from
five independent experiments.
doi:10.1371/journal.pone.0062305.g005
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chromosomal deletion or mutation of the cognate gene will
guarantee complete removal of the protein. We anticipate that the
efficiency of protein replacement using the snoMEN strategy can
be enhanced in future by further improvements in the vector
design but the present study already illustrates valuable applica-
tions of the current technology.
In this study the data suggest that snoMEN might modulate
target gene expression via a mechanism involving Ago2 and/or
Upf1 (Figure 4). Although both Ago2 and Upf1 localise mainly in
the cytoplasm, where they function for RNA interference
[6,7,8,39] and NMD [30,31,32] respectively, analysis of the
spatial proteome of human cells show that a proportion (,30–
40%) of both Ago2 and Upf1 proteins may also localise in the
nucleus [40,41] [analysed within Peptracker ( [42])]. In addition,
reports of nuclear functions for Ago2 and Upf1 are currently
expanding [43,44,45]. It might be possible that snoMEN RNA
interference occurred by an Ago2 dependent RNA cleavage event
and/or by blocking splicing of target mRNA involved in the Upf1
NMD pathway. Further study is necessary to define how Ago2
and/or Upf1 may be involved in the snoMEN mechanism of
action.
Characterisation of snoMEN-PR stable cell lines showed that
stable snoMEN expression does not prevent or reduce cell growth,
or alter the expression profile of a wide range of genes, as
measured by a quantitative MS approach (Figure 2E and Figure
S1B). The relatively high dose of siRNA often required for high
efficiency gene silencing may saturate endogenous RNAi pathways
leading to indirect effects on cell growth and gene expression [6].
However, the snoMEN system benefits from the fact that
endogenous box C/D snoRNAs are highly abundant nuclear
RNAs that are efficiently processed from within introns of many
different protein-coding cellular pre-mRNAs. M box-modified
snoRNAs are thus processed efficiently from vector transcripts
with reduced chance of overloading the endogenous snoRNA
processing machinery, which is consistent with the gene-profile
analysis in this study (Figure 2E and Figure S1B).
Establishment of UBF1 protein replacement stable cell lines,
HeLamCherry–UBF1-PR, allowed us to perform large-scale biochem-
ical experiments, e.g. pull-down analysis, which were previously
difficult for the reasons outlined above. We identified both known
and novel potential interaction partners of UBF1, either with, or
without, RNA polymerase I inhibition, i.e. Actinomicyn-D
treatment (Figure 5B, C). For example, known interaction
partners, e.g. RNA polymerase I (Pol I) subunits, showed no
change after Pol I inhibition; however, the interaction of UBF1
with some of the chromatin remodelling associated proteins, e.g.
SMARCA5/SNF2h, and WSTF, was decreased by Actinomycin-
D treatment (Figure 5C). WSTF and SNF2h are components of a
chromatin remodelling complex, termed WICH, that is recruited
to replication foci and prevents aberrant heterochromatin
formation shortly after DNA replication, thereby allowing
rebinding of factors to newly replicated DNA [46]. The complex
colocalises and interacts with RNA Pol I in nucleoli, and RNA
interference-mediated knock-down of WSTF impairs pre-rRNA
Figure 6. Features of snoMEN technology. Schematic diagram showing differences between the siRNA/shRNA and snoMEN systems. Arrows
show promoters for RNA polymerase III (shRNA) and RNA polymerase II (snoMEN), respectively. Red squares show the coding region, e.g. either
mCherry cDNA, or endogenous genes. Striped squares show non-coding exon region. The bars show non-coding regions, e.g. introns.
doi:10.1371/journal.pone.0062305.g006
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synthesis. Previous results indicate that a 2–3 MDa multiprotein
complex containing WSTF and SNF2h is required for rDNA
transcription [37]. These results, combined with our quantitative
pull-down assay of FP-tagged UBF1 protein, suggest that RNA
polymerase I inhibition by Actinomycin-D treatment disrupts the
interactions between UBF1 and chromatin remodelling complex-
es, but not the interaction of UBF1 with RNA polymerase I
subunits. Further study is needed to reveal the detailed mechanism
by which the RNA polymerase I machinery and UBF1-chromatin
remodelling complex interact. Furthermore, the SILAC pull-down
assay demonstrated an improved recovery of interacting proteins
using the protein replacement (U2OSGFP–SMN1-PR) stable cell line,
compared with the over-expression stable cell line,
U2OSGFP–SMN1 (Figure 5D and Figure S5). This occurs even
though FP-tagged SMN1 protein expression levels are almost 40%
lower in U2OSGFP–SMN1-PR than U2OSGFP–SMN1 cells (Figure 2D).
It is known that SMN1 forms an octamer complex both in vivo and
in vitro [38]. These results suggest that FP-tagged SMN1 is more
efficiently incorporated into the endogenous octamer complex in
the snoMEN protein replacement stable cell line, likely because
this system does not have to force the incorporation of FP-tagged
proteins into endogenous complexes (see model in Figure S5C).
Interestingly, a few proteins, e.g. coilin (Figure 5D), show the
opposite result, i.e. better recovery with the increased SMN1
expression levels as seen in the over-expression stable cell line,
U2OSGFP–SMN1. This may suggest that the proteins in this
category, such as coilin, mainly bind to free SMN1, but not to the
SMN1 complex. This would be an interesting point for future
investigation.
The snoMEN vectors provide an alternative tool for studying
gene expression that is complementary to existing methods. The
ability to quickly replace a significant proportion of essential
endogenous proteins with tagged and/or mutant versions in stable
cell lines is likely to prove particularly useful. For example, the
snoMEN approach could potentially be useful to express
catalytically-deficient versions of enzymes, such as methyl trans-
ferases, and endoRNases. We anticipate that further improve-
ments in snoMEN vectors design may increase further the
proportion of endogenous protein that can be replaced and we
foresee future applications for snoMEN vectors in basic gene-
expression research, in drug screening and target validation studies
and possibly also for gene therapy. All of these applications can
benefit from the ability to deliver knock-down and protein
replacement RNAs from a single vector encoding a single
transcript. The snoMEN vectors thus expand the repertoire of
technologies available for manipulating gene expression in
mammalian cells and can provide new opportunities for
overcoming current limitations. Furthermore, we also foresee a
development of snoMEN vectors to expand their utility and
applications, e.g. incorporating inducible promoters and delivery
using virus based vectors.
Supporting Information
Supplementary Materials and Methods
In vivo transcription assay. In vivo transcription assays were
performed as previously described (http://www.lamondlab.com/
f7protocols.htm). 1 mM of 5-fluorouridine (FU) was added into the
culture medium 15 min before fixation. Incorporated FU was detected
by staining with an Anti-BrU antibody (B2531, Sigma).
Figure S1 Gene-expression profile of snoMEN replacement
stable cell lines. (A) Distribution pattern of GFP-SMN1 signal
intensity of U2OSGFP–SMN1-PR stable cell line. Cytoplasmic GFP
signals were calculated from randomly selected cells (n = 42). Each
signal was normalised by DAPI signal. (B) Expression level
comparison of proteins detected by Mass spectrometry for
HeLamCherry–UBF1-PR versus HeLa cells. Each SILAC experiment
was independently repeated at least three times. Correlation
between protein ratios of SILAC experiments visualised on a 2D
logarithmic graph for all proteins identified as previously
demonstrated [48,49]. On the x and y axis, log2 (H/L ratio)
correlates with the enrichment in HeLamCherry–UBF1-PR versus
HeLa cells for experiment 1 and experiment 2, respectively. Graph
shows a distribution pattern of plot numbers. SILAC ratio values
of labelled proteins are listed in Table S3.
(TIF)
Figure S2 SiRNA and shRNA knock-down targeted to
endogenous SMN1 pre-mRNAs. (A–D) These are the same
experiment as in Figure 3C–F except the target gene is SMN1 in
U2OS cells. (A) Scrambled siRNA (Negative control siRNA) and
SMN1 siRNA (Dharmacon) were transfected as a negative and a
positive control, respectively. SMN1 Mbox siRNA-1 to -3 (siSM1–
3) have the same target sequence as SMN1 snoMEN from set1 to
set3, respectively (Figure 3A). Scale bar, 10 mm. Arrowhead: cells
showing knock-down. (B) Western blot analysis for siRNA
experiments. Detection of protein levels for endogenous SMN1
following transfection of U2OS cells using either Scrambled
siRNA (Control: lane1), SMN1 siRNA (siSMN1: lane2), SMN M
box siRNA-1 (siSM1: lane3), SMN M box siRNA-2 (siSM2:
lane4), and SMN M box siRNA-3 (siSM3: lane5). An equivalent
amount of U2OS extract was loaded for each lane and the
proteins separated by SDS PAGE, electroblotted onto membrane
and probed both with a monoclonal anti-SMN1 antibody and
with anti-tubulin as a loading control. Graph shows SMN1 signal
intensity normalised to the tubulin signal measured from three
independent experiments. (C) A shRNA plasmid targeted to
SMN1 and no-endogenous target shRNA plasmid were transfect-
ed as a positive and negative control, respectively. SMN1 Mbox
shRNA-1 to -3 (shSM1–3) have the same target sequence as
SMN1 snoMEN from set1 to set3, respectively (Figure 3B). Scale
bar, 10 mm. Arrow: cells not showing knock-down, Arrowhead:
cells showing knock-down. (D) Western blot analysis for shRNA
experiments. Detection of protein levels for endogenous SMN1
following transfection of U2OS cells using either Scrambled
shRNA (Control: lane1), SMN1 shRNA (shSMN1: lane2), SMN
M box shRNA-1 (shSM1: lane3), SMN M box shRNA-2 (shSM2:
lane4), and SMN M box shRNA-3 (shSM3: lane5). An equivalent
amount of U2OS extract was loaded for each lane and the
proteins separated by SDS PAGE, electroblotted onto membrane
and probed both with a monoclonal anti-SMN1 antibody and
with anti-tubulin as a loading control. Graph shows SMN1 signal
intensity normalised to the tubulin signal measured from three
independent experiments.
(TIF)
Figure S3 SnoRNA expression analysis after Fibrillarin knock-
down treatment. qRT-PCR was performed to measure snoRNA
expression level after treatment with scramble siRNA (Control)
and Fibrillarin siRNA. Equal amounts of total RNA from
U2OSGFP–SMN1-PR cells, extracted following siRNA treatment,
was used for qRT-PCR reactions. Graph shows the snoRNA
expression ratio between control and fibrillarin siRNA experi-
ments measured from four independent experiments. SnoRNA
HBII-180C (snoMEN backbone) specific primers and GAPDH
mRNA specific primers, as a loading control, were used for
amplification.
(TIF)
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Figure S4 Optimisation of RNA polymerase I inhibition using
low concentration Actinomycin-D treatment. (A) In vivo transcrip-
tion assay with/without Actinomycin-D treatment in HeLa cells.
HeLa cells were treated either with ethanol (EtOH) as a negative
control, or with Actinomycin-D (0.01 mg/ml) for each time point:
30 min, 1 hr, and 2 hr. Transcription in the cells was detected via
incorporation of 5-fluorouridine. Two hours following Actinomy-
cin-D treatment, the nucleolar signal had disappeared (arrow).
Scale bar indicates 14 mm. (B) Identification of pre-rRNA
transcriptions. Northern blot analysis was performed to decide a
time point of pre-rRNA inhibition by Actinomycin-D. Each pre-
rRNA was detected by using probes specific to 5.8S, 18S, and 28S
rRNAs. U3 snoRNA was also detected as a loading control. (C)
Specific RNA polymerase I inhibition was confirmed by imaging
fibrillarin and coilin localisation patterns. Fibrillarin accumulated
only in nucleoli after low concentration Actinomycin-D treatment
for 2 hr (arrow); however, the accumulation of coilin that should
occur at the nucleolar cap on inhibition of RNA polymerases I, II
and III with high concentration Actinomycin-D treatment (1 mg/
ml) [28], was not seen.
(TIF)
Figure S5 Characterisation of FP–protein complexes in replace-
ment stable cell lines by Quantitative SILAC Proteomic analysis.
(A) SILAC result of GFP–SMN1 complex pull-down assay
visualised on a 2D logarithmic graph. On the x axis, log2 (H/L
ratio) correlates with the enrichment in GFP–SMN1 IP with
protein replacement versus control IP. On the y axis, log2 (M/L
ratio) correlates with the enrichment in GFP–SMN1 IP versus
control IP without replacement. The bait, SMN1, is highlighted in
green, and a red line separates the proteins whose interaction with
SMN1 is increased (above the line), or decreased (below) by
protein replacement. SMN1 binding proteins which were
identified and quantified are highlighted in B. SILAC ratio values
of labelled proteins are listed in Table S4. (B) The graph
[expanded top right segment of (a)] shows SILAC fold change
ratio for known SMN binding proteins in the GFP–SMN1 IP. (C)
The model of immuno–precipitation of endogenous SMN1
complex.
(TIF)
Table S1 The list of SILAC ratio values of labelled
proteins described in Figure 2E.
(XLSX)
Table S2 The list of SILAC ratio values of top 10%
labelled proteins described in Figure 5B.
(XLSX)
Table S3 The list of SILAC ratio values of labelled
proteins described in Figure S1B.
(XLSX)
Table S4 The list of SILAC ratio values of top 10%
labelled proteins described in Figure S5A.
(XLSX)
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